---
title: "bioMerieux (OTCMKTS:BMXMF) Shares Gap Up   - Should You Buy?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277230152.md"
description: "bioMerieux (OTCMKTS:BMXMF) shares gapped up from $109.61 to $115.00 before market opening, with a trading volume of 1,012 shares. Analysts have downgraded the stock to a \"neutral\" rating, maintaining an average rating of \"Hold\". The stock is currently trading 4.9% higher, with a 50-day moving average of $120.59 and a 200-day moving average of $128.15. bioMerieux specializes in in vitro diagnostics, focusing on solutions for disease detection and patient health improvement."
datetime: "2026-02-27T17:00:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277230152.md)
  - [en](https://longbridge.com/en/news/277230152.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277230152.md)
---

# bioMerieux (OTCMKTS:BMXMF) Shares Gap Up   - Should You Buy?

bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $109.61, but opened at $115.00. bioMerieux shares last traded at $115.00, with a volume of 1,012 shares trading hands.

## Wall Street Analysts Forecast Growth

Separately, BNP Paribas Exane downgraded bioMerieux to a "neutral" rating in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, bioMerieux has an average rating of "Hold".

**Check Out Our Latest Report on BMXMF**

## bioMerieux Trading Up 4.9%

The stock's 50-day moving average price is $120.59 and its 200-day moving average price is $128.15. The company has a current ratio of 2.27, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08.

## About bioMerieux

(Get Free Report)

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.

## Read More

-   Five stocks we like better than bioMerieux
-   The gold chart Wall Street is terrified of…
-   America’s 1776 happening again
-   This makes me furious
-   Buy this Gold Stock Before May 2026
-   What a Former CIA Agent Knows About the Coming Collapse

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in bioMerieux Right Now?

Before you consider bioMerieux, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.

While bioMerieux currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [BIO.US](https://longbridge.com/en/quote/BIO.US.md)

## Related News & Research

- [Aqua Bio Technology Registers Share Capital Increase After Subsequent Offering](https://longbridge.com/en/news/282325318.md)
- [Lilly to acquire CrossBridge Bio for up to $300m](https://longbridge.com/en/news/282813734.md)
- [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)
- [Is Unity Software Stock a Buy, Sell, or Hold on VR Partnership with Meta Platforms?](https://longbridge.com/en/news/282705110.md)
- [investingLive Asia-Pacific FX news wrap: Doubts over Islamabad talks this weekend](https://longbridge.com/en/news/282285547.md)